AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34810368 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl siloxane
Number of subjects: 30
Study 34810368 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyether
Number of subjects: 30
Study 34810368 — intervention group
Group type: COMPARATOR
Intervention: Comparison between wax and polyvinyl siloxane
Number of subjects: 30
Study 34810368 — intervention group
Group type: COMPARATOR
Intervention: Comparison between wax and polyether
Number of subjects: 30
Study 34810368 — intervention group
Group type: COMPARATOR
Intervention: Comparison between polyvinyl siloxane and polyether
Number of subjects: 30
Study 32310283 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by alternative care practitioners (ACPs)
Number of subjects: 156
Study 32310283 — intervention group
Group type: COMPARATOR
Intervention: Adherent patients to PAP therapy
Number of subjects: 156
Study 34864978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25 hours)
Number of subjects: 120
Study 34864978 — intervention group
Group type: COMPARATOR
Intervention: Fast thrombolytic regimen (50 mg of rtPA infused in 6 hours)
Number of subjects: 120
Study 33446305 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 5310
Study 33446305 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR in patients with severe coronary artery disease (SevCAD)
Number of subjects: 5310
Study 33446305 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR in patients with concomitant ascending aorta replacement (CAAR)
Number of subjects: 5310
Study 33446305 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR in patients with non-tricuspid aortic valve (NTAV)
Number of subjects: 5310
Study 33446305 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR in patients with concomitant mitral/tricuspid valve (CMTV)
Number of subjects: 5310
Study 35487945 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a trauma film (COVID-19 related footage)
Number of subjects: 70
Study 32917529 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592
Study 32917529 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592
Study 36318424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 143
Study 36318424 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 143
Study 34162831 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-stage orally administered drugs targeting inhibitor of apoptosis proteins
Number of subjects: 0
Study 34162831 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary human liver organoid models
Number of subjects: 0
Study 36321647 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam alone
Number of subjects: 11
Study 36321647 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam with Ablative Fractional Laser (AFL) treatment
Number of subjects: 11
Study 36321647 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol‐Betamethasone Dipropionate (Cal/BD) foam
Number of subjects: 11
Study 33649444 — intervention group
Group type: EXPERIMENTAL
Intervention: Journal provided
Number of subjects: 100
Study 33649444 — intervention group
Group type: COMPARATOR
Intervention: No journal (control group)
Number of subjects: 100
Study 32138709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment in children with long-QT syndrome
Number of subjects: 51
Study 32138709 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study 32138709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing test with a cut-off of 440 ms
Number of subjects: 51
Study 33845856 — intervention group
Group type: EXPERIMENTAL
Intervention: EYE‐2 intervention + standardised EIP service
Number of subjects: 0
Study 33845856 — intervention group
Group type: COMPARATOR
Intervention: Standardised EIP service alone
Number of subjects: 0
Study 83012907 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (PN) 800 mg in two divided doses
Number of subjects: 0
Study 83012907 — intervention group
Group type: COMPARATOR
Intervention: Methadone 10 mg
Number of subjects: 0
Study 83012907 — intervention group
Group type: COMPARATOR
Intervention: Methadone 20 mg
Number of subjects: 0
Study 34431926 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection technique without aspiration
Number of subjects: 148
Study 34431926 — intervention group
Group type: COMPARATOR
Intervention: Slow injection with aspiration
Number of subjects: 148
Study 32331042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 42mg
Number of subjects: 1073
Study 32331042 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1073
Study 32331042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 33745625 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein group (1.6 g of protein/kg/day)
Number of subjects: 45
Study 33745625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein group (0.8 g of protein/kg/day)
Number of subjects: 45
Study 35346353 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program (60 min, once a week for 12 weeks, and self-exercise twice a week)
Number of subjects: 42
Study 35346353 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 42
Study 35346353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 32592215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy protocol with 1 cycle (10 seconds freezing and thawing)
Number of subjects: 48
Study 32592215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy protocol with 2 cycles (10 seconds freezing and thawing)
Number of subjects: 48
Study 37587796 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral-pressure needleless connectors (NCs)
Number of subjects: 201
Study 37587796 — intervention group
Group type: COMPARATOR
Intervention: Negative-pressure needleless connectors (NCs)
Number of subjects: 201
Study 34900891 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended maintenance intervention delivered individually by an intervention coordinator
Number of subjects: 1038
Study 34900891 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance intervention
Number of subjects: 1038
Study 32267771 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens.
Number of subjects: 0
Study 32267771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory and oxygenation strategies.
Number of subjects: 0
Study 34283019 — intervention group
Group type: EXPERIMENTAL
Intervention: solriamfetol 37.5 mg (OSA only)
Number of subjects: 710
Study 34283019 — intervention group
Group type: EXPERIMENTAL
Intervention: solriamfetol 75 mg
Number of subjects: 710
Study 34283019 — intervention group
Group type: EXPERIMENTAL
Intervention: solriamfetol 150 mg
Number of subjects: 710
Study 34283019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 34981165 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT‐driven group
Number of subjects: 132
Study 34981165 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic surgery group
Number of subjects: 132
Study 34981165 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT‐driven management
Number of subjects: 132
Study 34981165 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT for non‐Hürthle cell nodules
Number of subjects: 132
Study 34981165 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT for Hürthle cell nodules
Number of subjects: 132
Study 34981165 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG‐PET/CT
Number of subjects: 132
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients receiving invasive mechanical ventilation (5625 patients, 15.9%)
Number of subjects: 64781
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients admitted to ICU (6849 patients, 19.4%)
Number of subjects: 64781
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 64781
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 64781
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 64781
Study 33301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with both azithromycin and hydroxychloroquine
Number of subjects: 64781
Study 35018575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contraction
Number of subjects: 18
Study 35018575 — intervention group
Group type: COMPARATOR
Intervention: Concentric contraction
Number of subjects: 18
Study 33081982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan meal (V-meal)
Number of subjects: 60
Study 33081982 — intervention group
Group type: COMPARATOR
Intervention: Conventional meat meal (M-meal)
Number of subjects: 60
Study 33081982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 60
Study 36058514 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with ten home visits over one year
Number of subjects: 223
Study 36058514 — intervention group
Group type: COMPARATOR
Intervention: Certified Asthma Educator (AE-C) intervention with two clinic sessions over one year
Number of subjects: 223
Study 36058514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CHW and AE-C interventions
Number of subjects: 223
Study 33882392 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring decision-making experiences in TPTL
Number of subjects: 10
Study 34881655 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of women categorized as professional
Number of subjects: 201
Study 34881655 — intervention group
Group type: COMPARATOR
Intervention: Evaluation of women categorized as sexy
Number of subjects: 201
Study 34342205 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal dissection group
Number of subjects: 30
Study 34342205 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery group
Number of subjects: 30
Study 32430078 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (bi-weekly) including aerobic training, strengthening, and cardiovascular exercises for 8 weeks.
Number of subjects: 0
Study 32430078 — intervention group
Group type: COMPARATOR
Intervention: Usual care/no intervention (control group).
Number of subjects: 0
Study 34737064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprifermin (recombinant FGF18), administered intra-articularly over a 2-year period.
Number of subjects: 284
Study 34737064 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered intra-articularly over a 2-year period.
Number of subjects: 284
Study 34737064 — intervention group
Group type: COMPARATOR
Intervention: Sprifermin vs Placebo in low PRO-C2 group.
Number of subjects: 284
Study 34737064 — intervention group
Group type: COMPARATOR
Intervention: Sprifermin vs Placebo in high PRO-C2 group.
Number of subjects: 284
Study 33281083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 2.5 units
Number of subjects: 9
Study 33281083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 5 units
Number of subjects: 9
Study 33281083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 10 units
Number of subjects: 9
Study 33281083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 20 units
Number of subjects: 9
Study 33281083 — intervention group
Group type: COMPARATOR
Intervention: Control (no hyaluronidase)
Number of subjects: 9
Study 34091813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexamethasone 8 mg (2 ml) with normal saline administered 1 hour before surgery
Number of subjects: 150
Study 34091813 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dexamethasone 8 mg (2 ml) administered 1 hour before surgery
Number of subjects: 150
Study 34091813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual dexamethasone 8 mg
Number of subjects: 150
Study 34091813 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular dexamethasone 8 mg
Number of subjects: 150
Study 35023094 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management program including stress- and diet-related psychoeducation, diaphragmatic breathing, guided imagery, progressive muscle relaxation, and cognitive reconstruction.
Number of subjects: 53
Study 35023094 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week stress management program
Number of subjects: 53
Study 35023094 — intervention group
Group type: COMPARATOR
Intervention: Type of surgery (partial or total mastectomy)
Number of subjects: 53
Study 35197354 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg vaginal micronised progesterone supplemented with 50 mg intramuscular progesterone per day
Number of subjects: 824
Study 35197354 — intervention group
Group type: COMPARATOR
Intervention: 800 mg vaginal micronised progesterone
Number of subjects: 824
Study 34526921 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) followed by Bright Light Therapy (BLT) (10,000 lux, 30 min/day) as add-on to standard treatment
Number of subjects: 33
Study 34526921 — intervention group
Group type: COMPARATOR
Intervention: Short sleep-hygiene consultation as add-on to standard treatment
Number of subjects: 33
Study 32548915 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIIIa on Day 2 after MI
Number of subjects: 146
Study 32548915 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIIIa levels
Number of subjects: 146
Study 32548915 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIIIa levels after 12 months
Number of subjects: 146
Study 32548915 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIIIa activity
Number of subjects: 146
Study 35272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine with cranberry capsules
Number of subjects: 182
Study 35272334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cranberry alone)
Number of subjects: 182
Study 35272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 32868176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 56
Study 32868176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 35944747 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center supervised exercise training incorporating majority aerobic but also muscle strengthening activities
Number of subjects: 99
Study 35944747 — intervention group
Group type: COMPARATOR
Intervention: Group health education control intervention
Number of subjects: 99
Study 33338464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intra-aortic balloon pump (IABP) implantation
Number of subjects: 200
Study 33338464 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive treatments
Number of subjects: 200
Study 32701140 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care neoadjuvant therapy consisting of taxane treatment followed by doxorubicin and cyclophosphamide.
Number of subjects: 950
Study 32701140 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (taxane treatment without investigational agents).
Number of subjects: 950
Study 36282530 — intervention group
Group type: EXPERIMENTAL
Intervention: risankizumab 150 mg
Number of subjects: 964
Study 36282530 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 964
Study 33720373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 185
Study 33720373 — intervention group
Group type: COMPARATOR
Intervention: Assisted Referral to Community Outpatient Mental Health Care (ARC)
Number of subjects: 185
Study 32584180 — intervention group
Group type: EXPERIMENTAL
Intervention: butorphanol tartrate (5 mg/kg)
Number of subjects: 13
Study 32584180 — intervention group
Group type: EXPERIMENTAL
Intervention: But‐P407 (12.5 mg/kg)
Number of subjects: 13
Study 32584180 — intervention group
Group type: COMPARATOR
Intervention: P407
Number of subjects: 13
Study 35380376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg) with ketamine (0.5 mg/kg) administered over 10 min followed by a maintenance dose of Dexmedetomidine (0.2‐0.8 µg/kg/h)
Number of subjects: 30
Study 35380376 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (1 µg/kg) administered over 10 min followed by a maintenance dose
Number of subjects: 30
Study 33641108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study with 7-day Holter ECGs
Number of subjects: 795
Study 33641108 — intervention group
Group type: COMPARATOR
Intervention: Case-control study with clinical prediction model
Number of subjects: 795
Study 33016783 — intervention group
Group type: EXPERIMENTAL
Intervention: AryoTrust® (6 mg/kg)
Number of subjects: 60
Study 33016783 — intervention group
Group type: COMPARATOR
Intervention: Herceptin® (6 mg/kg)
Number of subjects: 60
Study 33016783 — intervention group
Group type: EXPERIMENTAL
Intervention: AryoTrust®
Number of subjects: 60
Study 33016783 — intervention group
Group type: COMPARATOR
Intervention: Herceptin®
Number of subjects: 60
Study 35969460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo condition (interactive website with stigma-related content)
Number of subjects: 263
Study 35969460 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma condition (noninteractive website with stigma-related content)
Number of subjects: 263
Study 35969460 — intervention group
Group type: EXPERIMENTAL
Intervention: Interact condition (interactive website without stigma-related content)
Number of subjects: 263
Study 35969460 — intervention group
Group type: COMPARATOR
Intervention: Control condition (noninteractive website without stigma-related content)
Number of subjects: 263
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes >8 years
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes complications
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Negligence of blood glucose test at home
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor self-care behavior
Number of subjects: 423
Study 33630936 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor self-efficacy
Number of subjects: 423
Study 34333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Social justice and race equity training (n = 49)
Number of subjects: 99
Study 34333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Training attendees (n = 23)
Number of subjects: 99
Study 34333792 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 99
Study 34333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Training condition (attendees)
Number of subjects: 99
Study 32812846 — intervention group
Group type: EXPERIMENTAL
Intervention: VR environments at 0 ft (VR0)
Number of subjects: 19
Study 32812846 — intervention group
Group type: EXPERIMENTAL
Intervention: VR environments at 40 ft (VR40)
Number of subjects: 19
Study 32812846 — intervention group
Group type: EXPERIMENTAL
Intervention: VR environments at 120 ft (VR120)
Number of subjects: 19
Study 32812846 — intervention group
Group type: COMPARATOR
Intervention: No VR
Number of subjects: 19
Study 32812846 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Sickness Questionnaire (SSQ)
Number of subjects: 19
Study 32812846 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence Questionnaire (PQ)
Number of subjects: 19
Study 35545356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) as an addition to usual care
Number of subjects: 33
Study 35545356 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 32297556 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent HCV infection confirmed by both medical records and self-reports
Number of subjects: 181
Study 32297556 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepant HCV results
Number of subjects: 181
Study 36360712 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey participation
Number of subjects: 102
Study 36360712 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 102
Study 32673171 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 83
Study 32673171 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study 35027515 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT) protocol using DCO2 and SCvo2
Number of subjects: 100
Study 35027515 — intervention group
Group type: COMPARATOR
Intervention: Conventional goal-directed care (control group)
Number of subjects: 100
Study 33597333 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Thoracic Epidural Analgesia (TEA)
Number of subjects: 86
Study 33597333 — intervention group
Group type: COMPARATOR
Intervention: Continuous Paravertebral Block (PVB)
Number of subjects: 86
Study 33104651 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Fabry‐Perot fiber‐optic sensor
Number of subjects: 3
Study 33104651 — intervention group
Group type: EXPERIMENTAL
Intervention: Another sensor in the same batch
Number of subjects: 3
Study 32394780 — intervention group
Group type: EXPERIMENTAL
Intervention: ITP group (intensive training program)
Number of subjects: 390
Study 32394780 — intervention group
Group type: EXPERIMENTAL
Intervention: ITP+ group (intensive training program and educational video)
Number of subjects: 390
Study 32394780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study 32000140 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical resisted sprint (VRS)
Number of subjects: 48
Study 32000140 — intervention group
Group type: COMPARATOR
Intervention: Horizontal resisted sprint
Number of subjects: 48